Vnitr Lek 2026, 72(2):120-122 | DOI: 10.36290/vnl.2026.025

Fixed combination of rosuvastatin and perindopril - the next step in cardiovascular disease prevention

Jiří Vítovec
I. interní kardioangiologická klinika Lékařské fakulty MU a FN u sv. Anny v Brně Ústav farmakologie a toxikologie Farmaceutické fakulty MU, Brno

The combination of a statin and an ACE inhibitor represents a modern therapeutic approach to the simultaneous management of hypercholesterolemia and arterial hypertension - the two main risk factors for cardiovascular disease (CVD). The fixed-dose combination of rosuvastatin and perindopril provides comprehensive prevention of CVD in patients at high or very high risk. This combination offers synergistic effects on blood pressure and lipid levels, and its simplified regimen improves patient adherence. This article summarizes the pharmacological properties of both agents, the rationale and benefits of their fixed combination, clinical indications, and practical considerations for internal medicine practice.

Keywords: rosuvastatin, perindopril, fixed-dose combination, dyslipidaemia, hypertension, adherence, cardiovascular prevention.

Accepted: March 25, 2026; Published: April 8, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vítovec J. Fixed combination of rosuvastatin and perindopril - the next step in cardiovascular disease prevention. Vnitr Lek. 2026;72(2):120-122. doi: 10.36290/vnl.2026.025.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Souček M. Perindopril - dlouholetá jistota v léčbě hypertenze. Vnitř Lék. 2021;67(2):119-124. Go to original source...
    2. Vítovec J, Špinar J, Špinarová L. Perindopril a léčba kardiovaskulárních onemocnění - 25 let úspěšného působení v kardiologii. Kardiol Rev Int Med. 2018;20(3):218-222.
    3. Vráblík M. Rosuvastatin. Interv Akut Kardiol. 2009;8(4):204-207.
    4. Reiner Ž, Catapano AL, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias: 2023 update. Eur Heart J. 2023;44(36):3121-3202.
    5. Rosolová H. Výhody současné léčby hypertenze a hypercholesterolémie fixní kombinací. Vnitř Lék. 2022;68(1):64-67. Go to original source...
    6. Wohlfahrt P, Krajčoviechová A, Bruthans J, et al. Hypertenze a hypercholesterolémie v české populaci. Vnitř Lék. 2016;62:863-867.
    7. Toth PP, Granberry MC. Fixed-dose combination therapy in dyslipidemia and hypertension: improving cardiovascular risk reduction and patient adherence. Am J Cardiovasc Drugs. 2020;20(5):473-486.
    8. Vráblík M. Simultánní intervence více rizikových faktorů - cesta k účinnému snížení kardiovaskulárního rizika. Kardiol Rev Int Med. 2019;21:177-179.
    9. Vráblík M. Význam fixních kombinací na poli kardiovaskulární prevence. Vnitř Lék. 2019;65(12):809-814. Go to original source...
    10. Souček M, Novák J. Kombinační léčba perindopril/atorvastatin - cesta k účinnému snížení KV rizika. Med Praxi. 2020;17(2):93-96. Go to original source...
    11. Emberson J, Whincup P, Morris R, et al. Evaluating the impact of population and high-risk strategies for the primary prevention of cardiovascular disease. Eur Heart J. 2004;25(6):484-491. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.